Home / Featured

Radiotherapy and Locoregional Therapy

Where local control still decides outcomes: dose escalation and adaptive planning, short-course versus long-course scheduling, ablative, intra-arterial and bone-seeking radiopharmaceutical techniques, and when radiotherapy can safely be withheld.

11 articles in this topic

  • October 12, 2026Journal of Clinical OncologyRT CHARM, Alliance A221505 (NCT03414970)

    Hypofractionated Postmastectomy Radiation Is Non-Inferior for 24-Month Reconstruction Complications: The RT CHARM Randomized Trial

    RT CHARM (Alliance A221505) randomized 898 patients to conventional postmastectomy radiation (50 Gy in 25 fractions) or hypofractionated radiation (42.56 Gy in 16 fractions) after mastectomy with planned or completed breast reconstruction. Among 825 evaluable patients, the 24-month reconstruction complication rate was 12.3% with hypofractionation vs 10.2% with conventional radiation (difference −2.1%, 95% CI −6.5% to 2.2%), meeting the prespecified 10% non-inferiority margin (p = 0.0001).

  • October 7, 2026Journal of Clinical OncologyNRG Oncology–BR002 (randomized phase II/III), NCT02364557

    Metastasis-Directed Ablation Adds No Progression-Free Survival Benefit in Oligometastatic Breast Cancer: Randomized NRG-BR002 Trial

    NRG-BR002 was a randomized phase II/III trial of 129 patients with oligometastatic breast cancer (125 eligible; 65 vs 60) comparing first-line systemic therapy alone with the same therapy plus ablation of all metastases by SBRT or surgery. At the phase II analysis (72 PFS events), median PFS was 23.0 months without ablation versus 19.5 months with ablation (HR 0.92; 95% CI, 0.57–1.47; 1-sided P = .36; stratified P = .42).

  • October 10, 2026Journal of Clinical OncologyEXTEND (primary aggregated analysis of all baskets), NCT03599765

    Metastasis-Directed Therapy Improves Progression-Free Survival but Not Overall Survival in Oligometastatic Disease, With an Inconclusive Kidney Basket: Phase II EXTEND Trial

    EXTEND was an investigator-initiated, multicenter, open-label, six-basket phase II randomized trial of metastasis-directed therapy (MDT) added to standard of care (SOC) in oligometastatic solid tumors. In the aggregated per-protocol population (n = 334; 166 vs 168), progression-free survival favored MDT + SOC: HR 0.54 (95% CI 0.41 to 0.72), P < .001, with median PFS 25.40 vs 14.00 months at a median follow-up of 53 months.

  • September 20, 2026Journal of Clinical OncologyLAANTERN (NCT02392078)

    Largest LITT Registry Shows Complete Ablation and Smaller Tumors Drive Survival Gains

    A prospective, 25-center registry analysis of 787 patients treated with laser interstitial thermal therapy (LITT) for primary or metastatic brain tumors — the largest such analysis to date — found that how completely a tumor is ablated, and how small it is to begin with, are the strongest drivers of survival after the procedure.

  • July 27, 2026Journal of Clinical OncologyNCT04071223

    Radium-223 Fails to Improve Skeletal Outcomes When Added to Cabozantinib in Metastatic Renal Cell Carcinoma

    The phase 2 RADICAL trial (Alliance A031801) tested whether adding the bone-targeted radiopharmaceutical radium-223 to cabozantinib would reduce skeletal morbidity in metastatic renal cell carcinoma (mRCC) with bone metastases. The study closed early for futility after a prespecified interim analysis.

  • August 20, 2026Journal of Clinical OncologyNRG Oncology/RTOG 0848 (NCT01013649)

    Adjuvant Chemoradiotherapy Misses Overall Survival Goal, but May Help Node-Negative Pancreatic Cancer

    The Step 2 randomization of NRG Oncology/RTOG 0848, a phase III trial of 354 patients with resected pancreatic head adenocarcinoma, found that adding chemoradiotherapy (CXRT) to adjuvant chemotherapy did not significantly improve overall survival across the full study population.

  • August 14, 2026Clinical Cancer ResearchFLARE-RT (NCT02773238)

    PET-Guided Adaptive Radiation Boost Improves Local Control in Unresectable NSCLC

    The Phase II FLARE-RT trial used mid-treatment FDG-PET response to selectively boost radiation dose (to 74 Gy, peak >90 Gy) only in the roughly one-third of unresectable NSCLC patients whose tumors were not responding, while treating responders with standard 60 Gy chemoradiation.

  • August 10, 2026Journal of Clinical OncologyNRG Oncology RTOG 0539 (NCT00895622)

    10-Year Data Validate Risk-Adapted Meningioma Strategy: Observation, Then Selective Radiotherapy

    Long-term follow-up (median exceeding 10 years) of NRG Oncology RTOG 0539 validates a risk-adapted meningioma strategy: observation after gross total or subtotal resection for low-risk (WHO grade 1) disease, and radiotherapy for intermediate- and high-risk disease.

  • August 6, 2026Journal of Clinical OncologySTELLAR (NCT02533271)

    Short-Course Radiotherapy-Based TNT Improves 5-Year Overall Survival in Locally Advanced Rectal Cancer

    The phase III STELLAR trial (NCT02533271) randomly assigned 591 patients with distal or middle-third locally advanced rectal cancer to a short-course radiotherapy-based total neoadjuvant therapy regimen (SCRT-TNT) or standard long-course chemoradiotherapy (CRT); this update reports 5-year outcomes at a median follow-up of 68.7 months.

  • July 30, 2026JAMA OncologyTORCH (NCT02435953)

    TACE Plus Thermal Ablation Nearly Halves Progression Risk in Intermediate-Stage Liver Cancer

    Phase 3 TORCH trial (241 patients, two tertiary centers in China, enrolled 2015-2024) randomized adults with unresectable, liver-confined, intermediate-stage (BCLC stage B) hepatocellular carcinoma 1:1 to transarterial chemoembolization (TACE) plus sequential radiofrequency ablation versus TACE alone.

  • July 13, 2026JAMA OncologyTREASURE (AIO-TRK-0320; NCT04462276)

    Adding Consolidative Thoracic Radiotherapy to Atezolizumab Maintenance Increases Toxicity Without Survival Benefit in Extensive-Stage SCLC: The Phase 2 TREASURE Trial

    Multicenter, open-label, randomized phase 2 trial (TREASURE, AIO-TRK-0320) at 20 sites in Germany and Austria testing whether adding consolidative thoracic radiotherapy (TRT, 30 Gy in 10 fractions) to atezolizumab maintenance improves overall survival in extensive-stage small cell lung cancer (ES-SCLC) after induction chemoimmunotherapy; 96 patients screened, 68 randomized 1:1

Cancer types covered: Breast Cancer · Prostate Cancer · Pancreatic Cancer · Kidney Cancer · Brain Cancer · Lung Cancer · Colorectal Cancer · Hepatocellular Carcinoma